Antares Pharma to Present at the 2015 RBC Capital Markets’ Global Healthcare Conference
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present a corporate overview at the RBC Capital Markets’ Global Healthcare Conference on Wednesday February 25, 2015 at 4:05 pm Eastern Time.
A live webcast of the presentation will be available via the “Investor Information/Webcasts” page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares’ website for 90 days following the presentation.
About Antares Pharma
Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company markets OTREXUPTM (methotrexate) injection for subcutaneous use in the treatment of adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. LEO Pharma markets OTREXUPTM to dermatologists for adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot(R) Testosterone for testosterone replacement therapy, and VIBEX(R) Sumatriptan for the acute treatment of migraines. The Company’s technology platforms include VIBEX(R) disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd. that includes VIBEX(R) epinephrine, exenatide multi-dose pen, and another undisclosed multi-dose pen. Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring Pharmaceuticals BV.
Sorry. No data so far.